{"rows":[{"id":1630,"title":"Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.","authors":"O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP","journal":"Contemporary clinical trials","publication_date":"2022-12-01","publication_year":2022,"doi":"10.1016/j.cct.2022.106976","pubmed_id":"36332827","openalex_id":"https://openalex.org/W4308040950","source_url":"https://pubmed.ncbi.nlm.nih.gov/36332827/","substance_tags":"psilocybin","topic_tags":"Addiction,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Safety","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:18","bibtex":null,"source_record_id":"PMID:36332827","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/36332827/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:36332827","source_url":"https://pubmed.ncbi.nlm.nih.gov/36332827/","doi":"10.1016/j.cct.2022.106976","pmid":"36332827","publication_date":"2022-12-01","importer_version":"2.1.3","text_redistributed":false}}],"total":1,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Contemporary clinical trials","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}